TY - JOUR
T1 - Update on pancreatic cancer
AU - Rocha Lima, Caio Max S.
AU - Centeno, Barbara
PY - 2002/7/20
Y1 - 2002/7/20
N2 - Pancreatic cancer remains the fourth leading cause of cancer deaths in males and females in the beginning of this new millennium. The 5-year survival for all stages remains less than 5%. The frequent diagnosis at late stages of the disease limits the role of surgery as a curative modality in pancreatic cancer. Despite recent advances, systemic treatment continues to have a limited role in the adjuvant setting, and chemotherapy is mostly palliative in advanced and metastatic pancreatic cancer patients. The differential diagnosis of pancreatic cancer and other gastrointestinal malignancies is, many times, challenging. Advances in the understanding of the disease biology may help in better diagnosis and treatment approaches. Clinical trials with molecular targeting agents are starting to emerge.
AB - Pancreatic cancer remains the fourth leading cause of cancer deaths in males and females in the beginning of this new millennium. The 5-year survival for all stages remains less than 5%. The frequent diagnosis at late stages of the disease limits the role of surgery as a curative modality in pancreatic cancer. Despite recent advances, systemic treatment continues to have a limited role in the adjuvant setting, and chemotherapy is mostly palliative in advanced and metastatic pancreatic cancer patients. The differential diagnosis of pancreatic cancer and other gastrointestinal malignancies is, many times, challenging. Advances in the understanding of the disease biology may help in better diagnosis and treatment approaches. Clinical trials with molecular targeting agents are starting to emerge.
UR - http://www.scopus.com/inward/record.url?scp=0035988127&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035988127&partnerID=8YFLogxK
U2 - 10.1097/00001622-200207000-00010
DO - 10.1097/00001622-200207000-00010
M3 - Review article
C2 - 12130928
AN - SCOPUS:0035988127
VL - 14
SP - 424
EP - 430
JO - Current Opinion in Oncology
JF - Current Opinion in Oncology
SN - 1040-8746
IS - 4
ER -